Rare, heterogeneously composed platinum group element alloy micronuggets (PGNs) occur in primitive meteorites, micrometeorites, and terrestrial impactite deposits. To gain insight into the nature of these phases, we developed a workflow for the characterization of PGNs using modern scanning electron microscopy (SEM) and energy-dispersive X-ray spectrometry at a low accelerating voltage of 6 kV. Automated feature analysis-a combination of morphological image analysis and elemental analysis with stage control-allowed us to detect PGNs down to 200 nm over a relatively large analysis area of 53 mm2 with a conventional silicon drift detector (SDD). Hyperspectral imaging with a high-sensitivity, annular SDD can be performed at low beam current (∼100 pA) which improves the SEM image resolution and minimizes hydrocarbon contamination. The severe overlapping peaks of the platinum group element L and M line families at 2-3 keV and the Fe and Ni L line families at <1 keV can be resolved by peak deconvolution. Quantitative elemental analysis can be performed at a spatial resolution of <80 nm; however, the results are affected by background subtraction errors for the Fe L line family. Furthermore, the inaccuracy of the matrix correction coefficients may influence standards-based quantification with pure element reference samples.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/micmic/ozad088 | DOI Listing |
Membranes (Basel)
November 2024
Graduate Institute of Precision Engineering, National Chung Hsing University, Taichung City 402, Taiwan.
This work aims at the effects of anion-exchange membranes (AEMs) and ionomer binders on the catalyst electrodes for anion-exchange membrane fuel cells (AEMFCs). In the experiments, four metal catalysts (nano-grade Pt, PtRu, PdNi and Ag), four AEMs (aQAPS-S8, AT-1, X37-50T and X37-50RT) and two alkaline ionomers (aQAPS-S14 and XB-7) were used. They were verified through several technical parameters examination and cell performance comparison for the optimal selection of AMEs.
View Article and Find Full Text PDFMethods Protoc
December 2024
Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Pécs, Honvéd Street 1, H-7624 Pécs, Hungary.
An electrochemical investigation of 1,2- and 1,4-dihydroxybenzenes was carried out with platinum macro- and microelectrodes using square wave and cyclic voltammetry techniques. Furthermore, the effect of the two solvents-acetic acid and ethyl acetate-was compared. When using square wave voltammetry, signals only appeared at lower frequencies and only when the supporting electrolyte was in excess, as expected due to the relatively low permittivity of the used solvents.
View Article and Find Full Text PDFCurr Oncol
December 2024
Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy.
Baseline thyroid function, as measured by the fT3 to fT4 ratio, has been shown to influence the prognosis of advanced cancer patients receiving active treatments. Although immune checkpoint blockade can alter the balance of thyroid hormones, this interaction has not been thoroughly investigated. The present research sought to determine whether changes in the fT3/fT4 ratio could affect the survival outcomes of patients with advanced non-small cell lung cancer (NSCLC) who were undergoing pembrolizumab-based therapies.
View Article and Find Full Text PDFCancer Res Treat
December 2024
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Purpose: Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.
View Article and Find Full Text PDFNPJ Precis Oncol
December 2024
Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
PARP inhibitors (PARPi) have shown efficacy in tumours harbouring mutations in homologous recombination repair (HRR) genes. Somatic HRR mutations have been described in patients with Non-Small Cell Lung Cancer (NSCLC), but PARP inhibitors (PARPi) are not yet a therapeutic option. Here we assessed the homologous recombination status of early-stage NSCLC and explored the therapeutic benefit of PARPi in preclinical models.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!